Large analyses and midstage data presented at nephrology meetings reinforced momentum in kidney therapeutics. A comprehensive study supports routine SGLT2 inhibitor use across a range of glomerular filtration rates and albuminuria levels, showing consistent renal and cardiovascular benefits for patients with and without diabetes. The data argue for broader class adoption in CKD management. In parallel, Takeda reported Phase Ib results for mezagitamab (TAK‑079), an anti‑CD38 antibody, showing sustained kidney function up to 18 months after treatment ended in patients with primary IgA nephropathy—an early signal of possible disease modification. The findings together highlight both small‑molecule and biologic paths to altering kidney disease trajectories and will inform larger outcome trials and regulatory discussions on labeling and treatment guidelines.